{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T02:25:47Z","timestamp":1794104747221,"version":"4.8.0"},"reference-count":102,"publisher":"Bentham Science Publishers Ltd.","issue":"11","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CMC"],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:sec>\n<jats:title\/>\n<jats:p>Drug repurposing has lately received increasing interest in several diseases especially in\ncancers, due to its advantages in facilitating the development of new therapeutic strategies, by\nadopting a cost-friendly approach and avoiding the strict Food and Drug Administration (FDA)\nregulations. Acriflavine (ACF) is an FDA approved molecule that has been extensively studied\nsince 1912 with antiseptic, trypanocidal, anti-viral, anti-bacterial and anti-cancer effects. ACF has\nbeen shown to block the growth of solid and hematopoietic tumor cells. Indeed, ACF acts as an\ninhibitor of various proteins, including DNA-dependent protein kinases C (DNA-PKcs), topoisomerase\nI and II, hypoxia-inducible factor 1&amp;#945; (HIF-1&amp;#945;), in addition to its recent discovery as an\ninhibitor of the signal transducer and activator of transcription (STAT). Chronic myeloid leukemia\n(CML) is a clonal myeloproliferative disorder characterized by the expression of the constitutively\nactive tyrosine kinase BCR-ABL. This protein allows the activation of several signaling pathways\nknown for their role in cell proliferation and survival, such as the JAK\/STAT pathway. CML therapy,\nbased on tyrosine kinase inhibitors (TKIs), such as imatinib (IM), is highly effective. However,\n15% of patients are refractory to IM, where in some cases, 20-30% of patients become resistant.\nThus, we suggest the repurposing of ACF in CML after IM failure or in combination with IM\nto improve the anti-tumor effects of IM. In this review, we present the different pharmacological\nproperties of ACF along with its anti-leukemic effects in the hope of its repurposing in CML therapy.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/0929867327666200908114411","type":"journal-article","created":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T04:27:29Z","timestamp":1599625649000},"page":"2218-2233","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Repurposing of Acriflavine to Target Chronic Myeloid Leukemia Treatment"],"prefix":"10.2174","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9015-4967","authenticated-orcid":true,"given":"Rawan","family":"Nehme","sequence":"first","affiliation":[{"name":"Universite de Tours, EA7501 GICC, Tours,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8060-5987","authenticated-orcid":true,"given":"Rawan","family":"Hallal","sequence":"additional","affiliation":[{"name":"Universite de Tours, EA7501 GICC, Tours,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4379-240X","authenticated-orcid":true,"given":"Maya","family":"El Dor","sequence":"additional","affiliation":[{"name":"Universite de Tours, EA7501 GICC, Tours,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5008-6944","authenticated-orcid":true,"given":"Firas","family":"Kobeissy","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Genetics, Faculty of Medicine, American University of Beirut, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6047-1718","authenticated-orcid":true,"given":"Fabrice","family":"Gouilleux","sequence":"additional","affiliation":[{"name":"Universite de Tours, EA7501 GICC, Tours,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6984-7096","authenticated-orcid":true,"given":"Fr\u00e9d\u00e9ric","family":"Mazurier","sequence":"additional","affiliation":[{"name":"Universite de Tours, EA7501 GICC, Tours,France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9887-072X","authenticated-orcid":true,"given":"Kazem","family":"Zibara","sequence":"additional","affiliation":[{"name":"PRASE, Lebanese University, Beirut,Lebanon"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1016\/j.drudis.2015.05.001]","volume":"20","author":"Langedijk J.","year":"2015","unstructured":"Langedijk J.; Mantel-Teeuwisse A.K.; Slijkerman D.S.; Schutjens M.H.D.B.; Drug repositioning and repurposing: terminology and definitions in literature. Drug Discov Today 2015,20(8),1027-1034","journal-title":"Drug Discov Today"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/bib\/bbx017]","volume":"19","author":"Lotfi Shahreza M.","year":"2018","unstructured":"Lotfi Shahreza M.; Ghadiri N.; Mousavi S.R.; Varshosaz J.; Green J.R.; A review of network-based approaches to drug repositioning. Brief Bioinform 2018,19(5),878-892","journal-title":"Brief Bioinform"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.phrs.2017.07.013","volume":"124","author":"Sleire L.","year":"2017","unstructured":"Sleire L.; F\u00f8rde H.E.; Netland I.A.; Leiss L.; Skeie B.S.; Enger P.\u00d8.; Drug repurposing in cancer. Pharmacol Res 2017,124,74-91","journal-title":"Pharmacol Res"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"7","DOI":"10.4103\/0019-5154.77543","volume":"56","author":"Rathi S.K.","year":"2011","unstructured":"Rathi S.K.; Acne vulgaris treatment: the current scenario. Indian J Dermatol 2011,56(1),7-13","journal-title":"Indian J Dermatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1310\/hpj5108-628","volume":"51","author":"Damery E.","year":"2016","unstructured":"Damery E.; Solimando D.A.; Jr.; Waddell, J.A. Arsenic trioxide and tretinoin (AsO\/ATRA) for acute promyelocytic leukemia (APL). Hosp Pharm 2016,51(8),628-632","journal-title":"Hosp Pharm"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"2096","DOI":"10.1039\/C5MB00306G","volume":"11","author":"Yeu Y.","year":"2015","unstructured":"Yeu Y.; Yoon Y.; Park S.; Protein localization vector propagation: a method for improving the accuracy of drug repositioning. Mol Biosyst 2015,11(7),2096-2102","journal-title":"Mol Biosyst"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1038\/nrd3405","volume":"10","author":"Pammolli F.","year":"2011","unstructured":"Pammolli F.; Magazzini L.; Riccaboni M.; The productivity crisis in pharmaceutical R","journal-title":"Nat Rev Drug Discov"},{"key":"ref=8","author":"Wong H-H.","year":"2014 Available at:","unstructured":"Wong H-H.; Jessup A.; Sertkaya A.; Birkenbach A.; Berlind A.; Eyraud J.;  Examination of clinical trial costs and barriers for drug development final  (Accessed June 15, 2020).2014 Available at: https:\/\/aspe.hhs.gov\/report\/examination-clinical-trial-costs-and-barriers-drug-development","journal-title":"Examination of clinical trial costs and barriers for drug development final"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1111\/bph.13798P MID: 28369768","volume":"175","author":"Cha Y.","year":"2018","unstructured":"Cha Y.; Erez T.; Reynolds I.J.; Kumar D.; Ross J.; Koytiger G.; Kusko R.; Zeskind B.; Risso S.; Kagan E.; Papapetropoulos S.; Grossman I.; Laifenfeld D.; Drug repurposing from the perspective of pharmaceutical companies. Br J Pharmacol 2018,175(2),168-180","journal-title":"Br J Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/sj.bjp.0707305","volume":"152","author":"Ekins S.","year":"2007","unstructured":"Ekins S.; Mestres J.; Testa B.; In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling. Br J Pharmacol 2007,152(1),9-20","journal-title":"Br J Pharmacol"},{"key":"ref=11","first-page":"654","volume":"10","author":"Shim J.S.","year":"2014","unstructured":"Shim J.S.; Liu J.O.; Recent advances in drug repositioning for the discovery of new anticancer drugs. Int J Bio Sci 2014,10(7),654-663","journal-title":"Int J Bio Sci"},{"key":"ref=12","first-page":"1232","volume":"14","author":"Xue H.","year":"2018","unstructured":"Xue H.; Li J.; Xie H.; Wang Y.; Review of drug repositioning approaches and resources. Int J Biol Sci 2018,14(10),1232-1244","journal-title":"Int J Biol Sci"},{"key":"ref=13","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019832226","volume":"9","author":"Grinnan D.","year":"2019","unstructured":"Grinnan D.; Trankle C.; Andruska A.; Bloom B.; Spiekerkoetter E.; Drug repositioning in pulmonary arterial hypertension: challenges and opportunities. Pulm Circ 2019,9(1)","journal-title":"Pulm Circ"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"273","DOI":"10.3389\/fonc.2017.00273","volume":"7","author":"Hernandez J.J.","year":"2017","unstructured":"Hernandez J.J.; Pryszlak M.; Smith L.; Yanchus C.; Kurji N.; Shahani V.M.; Molinski S.V.; Giving drugs a second chance: overcoming regulatory and financial hurdles in repurposing approved drugs as cancer therapeutics. Front Oncol 2017,7,273","journal-title":"Front Oncol"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/nrd.2018.168","volume":"18","author":"Pushpakom S.","year":"2018","unstructured":"Pushpakom S.; Iorio F.; Eyers P.A.; Escott K.J.; Hopper S.; Wells A.; Doig A.; Guilliams T.; Latimer J.; McNamee C.; Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov 2018,18(1),41-58","journal-title":"Nat Rev Drug Discov"},{"key":"ref=16","first-page":"192","volume":"1","author":"Yaseen S.","year":"2019","unstructured":"Yaseen S.; Akram S.; Drug repositioning, an approach for identification of new therapeutics. J Nat Appl Sci Pakistan  Available at: 2019,1(2),192-200 https:\/\/aspe.hhs.gov\/report\/examination-clinical-trial-costs-and-barriers-drug-development","journal-title":"J Nat Appl Sci Pakistan"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","volume":"3","author":"Ashburn T.T.","year":"2004","unstructured":"Ashburn T.T.; Thor K.B.; Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov 2004,3(8),673-683","journal-title":"Nat Rev Drug Discov"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1080\/17460441.2020.1704729","volume":"15","author":"Talevi A.","year":"2020","unstructured":"Talevi A.; Bellera C.L.; Challenges and opportunities with drug repurposing: finding strategies to find alternative uses of therapeutics. Expert Opin Drug Discov 2020,15(4),397-401","journal-title":"Expert Opin Drug Discov"},{"key":"ref=19","author":"Jafari R.M.","unstructured":"Jafari R.M.; Sheibani M.; Nezamoleslami S.; Shayesteh S.; Jand Y.; Dehpour A.R.;  Drug repositioning: a review  Available at:  http:\/\/www.jimc.ir\/article_ 66203.html","journal-title":"Drug repositioning: a review"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"19081","DOI":"10.3402\/jchimp.v2i3.19081","volume":"2","author":"Quianzon C.C.L.","year":"2012","unstructured":"Quianzon C.C.L.; Cheikh I.E.; History of current non-insulin medications for diabetes mellitus. J Community Hosp Intern Med Perspect 2012,2(3),19081","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref=21","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2014.9","volume":"5","author":"Amelio I.","year":"2014","unstructured":"Amelio I.; Gostev M.; Knight R.A.; Willis A.E.; Melino G.; Antonov A.V.; DRUGSURV: a resource for repositioning of approved and experimental drugs in oncology based on patient survival information. Cell Death Dis 2014,5(2)","journal-title":"Cell Death Dis"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1093\/BIB","volume":"19","author":"Musa A.","year":"2018","unstructured":"Musa A.; Ghoraie L.S.; Zhang S-D.; Glazko G.; Yli-Harja O.; Dehmer M.; Haibe-Kains B.; Emmert-Streib F.; A review of connectivity map and computational approaches in pharmacogenomics. Brief Bioinform 2018,19(3),506-523","journal-title":"Brief Bioinform"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/bib\/bbx017","volume":"19","author":"Lotfi Shahreza M.","year":"2018","unstructured":"Lotfi Shahreza M.; Ghadiri N.; Mousavi S.R.; Varshosaz J.; Green J.R.; A review of network-based approaches to drug repositioning. Brief Bioinform 2018,19(5),878-892","journal-title":"Brief Bioinform"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"D668","DOI":"10.1093\/nar\/gkj067","volume":"34","author":"Wishart D.S.","year":"2006","unstructured":"Wishart D.S.; Knox C.; Guo A.C.; Shrivastava S.; Hassanali M.; Stothard P.; Chang Z.; Woolsey J.; DrugBank: a comprehensive resource for in silico drug discovery and exploration. Nucleic Acids Res 2006,34(Database issue),D668-D672","journal-title":"Nucleic Acids Res"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1093\/nar\/26.1.33","volume":"26","author":"Mewes H.W.","year":"1998","unstructured":"Mewes H.W.; Hani J.; Pfeiffer F.; Frishman D.; MIPS: a database for protein sequences and complete genomes. Nucleic Acids Res 1998,26(1),33-37","journal-title":"Nucleic Acids Res"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2798","DOI":"10.1007\/s11095-015-1665-7","volume":"32","author":"Ai N.","year":"2015","unstructured":"Ai N.; Wood R.D.; Welsh W.J.; Identification of nitazoxanide as a group I metabotropic glutamate receptor negative modulator for the treatment of neuropathic pain: an in silico drug repositioning study. Pharm Res 2015,32(8),2798-2807","journal-title":"Pharm Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/47.1.1","volume":"47","author":"Wainwright M.","year":"2001","unstructured":"Wainwright M.; Acridine-A neglected antibacterial chromophore. J Antimicrob Chemother 2001,47(1),1-13","journal-title":"J Antimicrob Chemother"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0165-1110(79)90005-8","volume":"65","author":"Nasim A.","year":"1979","unstructured":"Nasim A.; Brychcy T.; Genetic effects of acridine compounds. Mutat Res 1979,65(4),261-288","journal-title":"Mutat Res"},{"key":"ref=29","first-page":"3","volume":"69","author":"Kumar R.","year":"2012","unstructured":"Kumar R.; Kaur M.; Kumari M.; Acridine: a versatile heterocyclic nucleus. Acta Pol Pharm 2012,69(1),3-9","journal-title":"Acta Pol Pharm"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1001\/jama.1929.02710090035014","volume":"93","year":"1929","unstructured":"Acriflavine hydrochloride and acriflavine base. J Am Med Assoc 1929,93(9),695-696","journal-title":"J Am Med Assoc"},{"key":"ref=31","doi-asserted-by":"publisher","author":"Browning C.H.","unstructured":"Browning C.H.; Cohen J.B.; Gaunt R.; Gulbransen R.; Relationships between antiseptic action and chemical constitution with special reference to compounds of the pyridine, quinoline, acridine and phenazine series. .Proc. R. Soc. London. Ser. B, Contain. Pap. a Biol. Character, 1922, 93(653), 329-366.","DOI":"10.1098\/rspb.1922.0025"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/S0140-6736(00)56423-X","volume":"227","author":"Assinder E.W.","year":"1936","unstructured":"Assinder E.W.; Birm M.D.; Acriflavine as a urinary antiseptic. Lancet 1936,227(5867),304-305","journal-title":"Lancet"},{"key":"ref=33","author":"Kozurkova M.","unstructured":"Kozurkova M.; Sabolova D.;  Acridine Isothiocyanates: Chemistry and Biology; Pavol Krastian Ed.; LAP LAMBERT Academic Publishing,2014."},{"key":"ref=34","author":"Mukherjee A.","year":"2013","unstructured":"Mukherjee A.; Sasikala W.D.; Proflavine - an overview. Adv Protein Chem Struct Biol 2013","journal-title":"Adv Protein Chem Struct Biol"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1002\/jat.3464","volume":"37","author":"Ko\u017eurkov\u00e1 M.","year":"2017","unstructured":"Ko\u017eurkov\u00e1 M.; Sabolov\u00e1 D.; Kristian P.; A review on acridinylthioureas and its derivatives: biological and cytotoxic activity. J Appl Toxicol 2017,37(10),1132-1139","journal-title":"J Appl Toxicol"},{"key":"ref=36","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-63953-6","author":"Je\u017eek J.","year":"2017","unstructured":"Je\u017eek J.; Hlav\u00e1\u010dek J.; \u0160ebest\u00edk J.;  Biomedical Applications of Acridines, 72 2017","journal-title":"Biomedical Applications of Acridines, 72"},{"key":"ref=37","author":"Albert A.","year":"1966","unstructured":"Albert A.;  The Acridines: Their Preparation, Physical, Chemical, and Biological Properties and Uses 1966","journal-title":"The Acridines: Their Preparation, Physical, Chemical, and Biological Properties and Uses"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"14978","DOI":"10.1038\/s41598-017-14990-w","volume":"7","author":"Mangraviti A.","year":"2017","unstructured":"Mangraviti A.; Raghavan T.; Volpin F.; Skuli N.; Gullotti D.; Zhou J.; Asnaghi L.; Sankey E.; Liu A.; Wang Y.; Lee D.H.; Gorelick N.; Serra R.; Peters M.; Schriefer D.; Delaspre F.; Rodriguez F.J.; Eberhart C.G.; Brem H.; Olivi A.; Tyler B.; HIF-1\u03b1- targeting acriflavine provides long term survival and radiological tumor response in brain cancer therapy. Sci Rep 2017,7(1),14978","journal-title":"Sci Rep"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1002\/jps.3080180703","volume":"18","author":"Collins G.W.","year":"1929","unstructured":"Collins G.W.; Stasiak A.; Comparative chemical examination of different brands of acriflavine hydrochloride (acriflavine) and acriflavine base (\u201cneutral\u201d acriflavine). J Am Pharm Assoc 1929,18(7),659-669","journal-title":"J Am Pharm Assoc"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1021\/cb500476q","volume":"9","author":"Dana S.","year":"2014","unstructured":"Dana S.; Prusty D.; Dhayal D.; Gupta M.K.; Dar A.; Sen S.; Mukhopadhyay P.; Adak T.; Dhar S.K.; Potent antimalarial activity of acriflavine in vitro and in vivo. ACS Chem Biol 2014,9(10),2366-2373","journal-title":"ACS Chem Biol"},{"key":"ref=41","first-page":"212","volume":"27","author":"Vicentini C.B.","year":"2019","unstructured":"Vicentini C.B.; Manfredini S.; Maritati M.; Di Nuzzo M.; Contini C.; Gonorrhea, a current disease with ancient roots: from the remedies of the past to future perspectives. Infez Med 2019,27(2),212-221","journal-title":"Infez Med"},{"key":"ref=42","year":"(Accessed\tdate: Jun 5, 2020.).","unstructured":"Acriflavine | antiseptic and dye | Britannica. Available at:(Accessed\tdate: Jun 5, 2020.). https:\/\/www.britannica.com\/science\/acriflavine"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/bmj.1.3045.571","volume":"1","author":"Watson D.","year":"1919","unstructured":"Watson D.; The treatment of gonorrhoea with acriflavine. BMJ 1919,1(3045),571-572","journal-title":"BMJ"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/0753-3322(89)90002-4","volume":"43","author":"Math\u00e9 G.","year":"1989","unstructured":"Math\u00e9 G.; Huppert J.; Chenu E.; Bourut C.; Amino acridines action on Friend\u2019s retrovirus in relation to their molecular ionization. Biomed Pharmacother 1989,43(4),235-236","journal-title":"Biomed Pharmacother"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/0753-3322(96)87662-1","volume":"50","author":"Math\u00e9 G.","year":"1996","unstructured":"Math\u00e9 G.; Pontiggia P.; Orbach-Arbouys S.; Triana K.; Ambetima N.; Morette C.; Hallard M.; Blanquet D.; AIDS therapy with two, three or four agent combinations, applied in short sequences, differing from each other by drug rotation. I. First of two parts: a phase I trial equivalent, concerning five virostatics: AZT, ddI, ddC, acriflavine and an ellipticine analogue. Biomed Pharmacother 1996,50(5),220-227","journal-title":"Biomed Pharmacother"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"9571","DOI":"10.1007\/s13277-014-2156-x","volume":"35","author":"Fan J.","year":"2014","unstructured":"Fan J.; Yang X.; Bi Z.; Acriflavine suppresses the growth of human osteosarcoma cells through apoptosis and autophagy. Tumour Biol 2014,35(10),9571-9576","journal-title":"Tumour Biol"},{"key":"ref=47","first-page":"665","volume":"23","author":"Thurber D.S.","year":"1930","unstructured":"Thurber D.S.; The results of the use of acriflavine hydrochloride in the treatment of undulant fever. Can Med Assoc J 1930,23(5),665-668","journal-title":"Can Med Assoc J"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1629","DOI":"10.1001\/jama.1919.02610470065029","volume":"73","author":"Quackenbos M.","year":"1919","unstructured":"Quackenbos M.; The use of acriflavine. J Am Med Assoc 1919,73(21),1629","journal-title":"J Am Med Assoc"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/1447-056X-10-6","volume":"10","author":"Leelavathi M.","year":"2011","unstructured":"Leelavathi M.; Le Y.; Tohid H.; Hasliza A.; Contact dermatitis presenting as non-healing wound: case report. Asia Pac Fam Med 2011,10(1),6","journal-title":"Asia Pac Fam Med"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1677\/joe.0.0300151]","volume":"30","author":"Nilsson O.","year":"1964","unstructured":"Nilsson O.; The acriflavine method, a rapid morphological test of the effect of oestrogen on the mouse uterus. J Endocrinol 1964,30(1),151-152","journal-title":"J Endocrinol"},{"key":"ref=51","first-page":"841","volume":"23","author":"Goldie H.","year":"1959","unstructured":"Goldie H.; Walker M.; Graham T.; Williams F.; Topical effect of acriflavine compounds on growth and spread of malignant cells. J Natl Cancer Inst 1959,23,841-855","journal-title":"J Natl Cancer Inst"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1111\/j.1349-7006.2011.02097.x","volume":"102","author":"Hassan S.","year":"2011","unstructured":"Hassan S.; Laryea D.; Mahteme H.; Felth J.; FryknAs, M.; Fayad, W.; Linder, S.; Rickardson, L.; Gullbo, J.; Graf, W.; P\u00e1hlman, L.; Glimelius, B.; Larsson, R.; Nygren, P. Novel activity of acriflavine against colorectal cancer tumor cells. Cancer Sci 2011,102(12),2206-2213","journal-title":"Cancer Sci"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"17910","DOI":"10.1073\/pnas.0909353106","volume":"106","author":"Lee K.","year":"2009","unstructured":"Lee K.; Zhang H.; Qian D.Z.; Rey S.; Liu J.O.; Semenza G.L.; Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization. Proc Natl Acad Sci USA 2009,106(42),17910-17915","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1093\/carcin\/bgu004","volume":"35","author":"Shay J.E.S.","year":"2014","unstructured":"Shay J.E.S.; Imtiyaz H.Z.; Sivanand S.; Durham A.C.; Skuli N.; Hsu S.; Mucaj V.; Eisinger-Mathason T.S.; Krock B.L.; Giannoukos D.N.; Simon M.C.; Inhibition of hypoxia-inducible factors limits tumor progression in a mouse model of colorectal cancer. Carcinogenesis 2014,35(5),1067-1077","journal-title":"Carcinogenesis"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"80521","DOI":"10.18632\/oncotarget.11825","volume":"7","author":"Guo X.","year":"2016","unstructured":"Guo X.; Xue H.; Shao Q.; Wang J.; Guo X.; Chen X.; Zhang J.; Xu S.; Li T.; Zhang P.; Gao X.; Qiu W.; Liu Q.; Li G.; Hypoxia promotes glioma-associated macrophage infiltration via periostin and subsequent M2 polarization by upregulating TGF-beta and M-CSFR. Oncotarget 2016,7(49),80521-80542","journal-title":"Oncotarget"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"10084","DOI":"10.3892\/ol.2018.8569","volume":"15","author":"Zargar P.","year":"2018","unstructured":"Zargar P.; Ghani E.; Mashayekhi F.J.; Ramezani A.; Eftekhar E.; Acriflavine enhances the antitumor activity of the chemotherapeutic drug 5-fluorouracil in colorectal cancer cells. Oncol Lett 2018,15(6),10084-10090","journal-title":"Oncol Lett"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"3341","DOI":"10.18632\/oncotarget.6490","volume":"7","author":"Weijer R.","year":"2016","unstructured":"Weijer R.; Broekgaarden M.; Krekorian M.; Alles L.K.; van Wijk A.C.; Mackaaij C.; Verheij J.; van der Wal A.C.; van Gulik T.M.; Storm G.; Heger M.; Inhibition of hypoxia inducible factor 1 and topoisomerase with acriflavine sensitizes perihilar cholangiocarcinomas to photodynamic therapy. Oncotarget 2016,7(3),3341-3356","journal-title":"Oncotarget"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"139","DOI":"10.3727\/096504014X13983417587366","volume":"22","author":"Yin T.","year":"2014","unstructured":"Yin T.; He S.; Shen G.; Wang Y.; HIF-1 dimerization inhibitor acriflavine enhances antitumor activity of sunitinib in breast cancer model. Oncol Res 2014,22(3),139-145","journal-title":"Oncol Res"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1007\/s00109-011-0855-y","volume":"90","author":"Wong C.C.L.","year":"2012","unstructured":"Wong C.C.L.; Zhang H.; Gilkes D.M.; Chen J.; Wei H.; Chaturvedi P.; Hubbi M.E.; Semenza G.L.; Inhibitors of hypoxia-inducible factor 1 block breast cancer metastatic niche formation and lung metastasis. J Mol Med (Berl) 2012,90(7),803-815","journal-title":"J Mol Med (Berl)"},{"key":"ref=60","first-page":"3549","volume":"34","author":"Lee C-J.","year":"2014","unstructured":"Lee C-J.; Yue C-H.; Lin Y-Y.; Wu J-C.; Liu J-Y.; Antitumor activity of acriflavine in human hepatocellular carcinoma cells. Anticancer Res 2014,34(7),3549-3556","journal-title":"Anticancer Res"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S0022-5347(17)74204-8","volume":"2","author":"Davis E.G.","year":"1918","unstructured":"Davis E.G.; Harrell B.E.; Acriflavine in the treatment of gonorrhoea - an experimental and clinical study. J Urol 1918,2(4),257-276","journal-title":"J Urol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/S0753-3322(99)80007-9","volume":"52","author":"Math\u00e9 G.","year":"1998","unstructured":"Math\u00e9 G.; Triana K.; Pontiggia P.; Blanquet D.; Hallard M.; Morette C.; Data of pre-clinical and early clinical trials of acriflavine and hydroxy-methyl-ellipticine reviewed, enriched by the experience of their use for 18 months to 6 years in combinations with other HIV1 virostatics. Biomed Pharmacother 1998,52(9),391-396","journal-title":"Biomed Pharmacother"},{"key":"ref=63","unstructured":"Richard Laboratoire M. Use of Acriflavine as an Anti-HIV Agent. Patent FR2711527A1, October 22,1993."},{"key":"ref=64","author":"Nunes C.P.","year":"2017","unstructured":"Nunes C.P.; dos \u00d3rg\u00e3os F.E.S.;  Clinical assessment of urinary antiseptics methenamine andmethylthioninium in recurrent cystitis Patent NCT03379389, December 20 2017","journal-title":"Clinical assessment of urinary antiseptics methenamine andmethylthioninium in recurrent cystitis Patent NCT03379389, December 20"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"S241","DOI":"10.1007\/s00277-015-2314-2","volume":"94","author":"H\u00f6glund M.","year":"2015","unstructured":"H\u00f6glund M.; Sandin F.; Simonsson B.; Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol 2015,94(Suppl. 2),S241-S247","journal-title":"Ann Hematol"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.exphem.2016.11.005","volume":"47","author":"Clarke C.J.","year":"2017","unstructured":"Clarke C.J.; Holyoake T.L.; Preclinical approaches in chronic myeloid leukemia: from cells to systems. Exp Hematol 2017,47,13-23","journal-title":"Exp Hematol"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1038\/nrc1567","volume":"5","author":"Ren R.","year":"2005","unstructured":"Ren R.; Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer 2005,5(3),172-183","journal-title":"Nat Rev Cancer"},{"key":"ref=68","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"Druker B.J.","year":"2001","unstructured":"Druker B.J.; Talpaz M.; Resta D.J.; Peng B.; Buchdunger E.; Ford J.M.; Lydon N.B.; Kantarjian H.; Capdeville R.; Ohno-Jones S.; Sawyers C.L.; Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001,344(14),1031-1037","journal-title":"N Engl J Med"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1097\/PPO.0000000000000165","volume":"22","author":"Pophali P.A.","year":"2016","unstructured":"Pophali P.A.; Patnaik M.M.; The role of new tyrosine kinase inhibitors in chronic myeloid leukemia. Cancer J 2016,22(1),40-50","journal-title":"Cancer J"},{"key":"ref=70","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","volume":"4","author":"Gambacorti-Passerini C.B.","year":"2003","unstructured":"Gambacorti-Passerini C.B.; Gunby R.H.; Piazza R.; Galietta A.; Rostagno R.; Scapozza L.; Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias. Lancet Oncol 2003,4(2),75-85","journal-title":"Lancet Oncol"},{"key":"ref=71","doi-asserted-by":"publisher","first-page":"4317","DOI":"10.3892\/ol.2019.10767","volume":"18","author":"Yu Z.","year":"2019","unstructured":"Yu Z.; Liu L.; Shu Q.; Li D.; Wang R.; Leukemia stem cells promote chemoresistance by inducing downregulation of lumican in mesenchymal stem cells. Oncol Lett 2019,18(4),4317-4327","journal-title":"Oncol Lett"},{"key":"ref=72","unstructured":"Sprycel (Dasatinib) Information | FDA. Available at: https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/sprycel-dasatinib-information"},{"key":"ref=73","unstructured":"Tasigna (nilotinib) FDA Approval History - Drugs.com. Avaialable at: (Accessed March 22, 2021) https:\/\/www.drugs.com\/history\/tasigna.html"},{"key":"ref=74","year":"2020","unstructured":"Ponatinib (marketed as Iclusig) Informaton | FDA. Available at:(Accessed date: August 9, 2020.). https:\/\/www.fda.gov\/drugs\/postmarket-drug-safety-information-patients-and-providers\/ponatinib-marketed-iclusig-informaton"},{"key":"ref=75","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.clml.2015.03.006","volume":"15","author":"Jabbour E.","year":"2015","unstructured":"Jabbour E.; Kantarjian H.; Cortes J.; Use of second- and third-generation tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia: an evolving treatment paradigm. Clin Lymphoma Myeloma Leuk 2015,15(6),323-334","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref=76","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1111\/j.2042-7158.1997.tb06783.x","volume":"49","author":"Kim S.G.","year":"1997","unstructured":"Kim S.G.; Kim C.W.; Ahn E.T.; Lee K.Y.; Hong E.K.; Yoo B.I.; Han Y.B.; Enhanced anti-tumour effects of acriflavine in combination with guanosine in mice. J Pharm Pharmacol 1997,49(2),216-222","journal-title":"J Pharm Pharmacol"},{"key":"ref=77","doi-asserted-by":"publisher","first-page":"10052","DOI":"10.1111\/jcmm.15612","volume":"24","author":"Hallal R.","year":"2020","unstructured":"Hallal R.; Nehme R.; Brachet-Botineau M.; Nehme A.; Dakik H.; Deynoux M.; Dello Sbarba P.; Levern Y.; Zibara K.; Gouilleux F.; Mazurier F.; Acriflavine targets oncogenic STAT5 signaling in myeloid leukemia cells. J Cell Mol Med 2020,24(17),10052-10062","journal-title":"J Cell Mol Med"},{"key":"ref=78","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/jat.3818","volume":"40","author":"Sabolova D.","year":"2020","unstructured":"Sabolova D.; Kristian P.; Kozurkova M.; Proflavine\/acriflavine derivatives with versatile biological activities. J Appl Toxicol 2020,40(1),64-71","journal-title":"J Appl Toxicol"},{"key":"ref=79","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1182\/blood-2016-10-745588","volume":"130","author":"Cheloni G.","year":"2017","unstructured":"Cheloni G.; Tanturli M.; Tusa I.; Ho DeSouza N.; Shan Y.; Gozzini A.; Mazurier F.; Rovida E.; Li S.; Dello Sbarba P.; Targeting chronic myeloid leukemia stem cells with the hypoxia-inducible factor inhibitor acriflavine. Blood 2017,130(5),655-665","journal-title":"Blood"},{"key":"ref=80","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0959-437X(00)00193-3","volume":"11","author":"Maxwell P.H.","year":"2001","unstructured":"Maxwell P.H.; Pugh C.W.; Ratcliffe P.J.; Activation of the HIF pathway in cancer. Curr Opin Genet Dev 2001,11(3),293-299","journal-title":"Curr Opin Genet Dev"},{"key":"ref=81","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fonc.2016.00041","volume":"6","author":"Deynoux M.","year":"2016","unstructured":"Deynoux M.; Sunter N.; HA(c)rault, O.; Mazurier, F. Hypoxia and hypoxia-inducible factors in leukemias. Front Oncol 2016,6(FEB),41","journal-title":"Front Oncol"},{"key":"ref=82","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/j.molcel.2010.09.022","volume":"40","author":"Majmundar A.J.","year":"2010","unstructured":"Majmundar A.J.; Wong W.J.; Simon M.C.; Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell 2010,40(2),294-309","journal-title":"Mol Cell"},{"key":"ref=83","doi-asserted-by":"publisher","first-page":"3316","DOI":"10.1182\/blood-2013-07-511907","volume":"123","author":"Ng K.P.","year":"2014","unstructured":"Ng K.P.; Manjeri A.; Lee K.L.; Huang W.; Tan S.Y.; Chuah C.T.H.; Poellinger L.; Ong S.T.; Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition. Blood 2014,123(21),3316-3326","journal-title":"Blood"},{"key":"ref=84","doi-asserted-by":"publisher","first-page":"2595","DOI":"10.1182\/blood-2011-10-387381","volume":"119","author":"Zhang H.","year":"2012","unstructured":"Zhang H.; Li H.; Xi H.S.; Li S.; HIF1\u03b1 is required for survival maintenance of chronic myeloid leukemia stem cells. Blood 2012,119(11),2595-2607","journal-title":"Blood"},{"key":"ref=85","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.stem.2011.02.006","volume":"8","author":"Wang Y.","year":"2011","unstructured":"Wang Y.; Liu Y.; Malek S.N.; Zheng P.; Liu Y.; Targeting HIF1\u03b1 eliminates cancer stem cells in hematological malignancies. Cell Stem Cell 2011,8(4),399-411","journal-title":"Cell Stem Cell"},{"key":"ref=86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0062717","volume":"8","author":"Kawada H.","year":"2013","unstructured":"Kawada H.; Kaneko M.; Sawanobori M.; Uno T.; Matsuzawa H.; Nakamura Y.; Matsushita H.; Ando K.; High concentrations of L-ascorbic acid specifically inhibit the growth of human leukemic cells via downregulation of HIF-1\u03b1 transcription. PLoS One 2013,8(4)","journal-title":"PLoS One"},{"key":"ref=87","doi-asserted-by":"publisher","first-page":"3685","DOI":"10.1158\/1078-0432.CCR-14-3022","volume":"21","author":"Coltella N.","year":"2015","unstructured":"Coltella N.; Valsecchi R.; Ponente M.; Ponzoni M.; Bernardi R.; Synergistic leukemia eradication by combined treatment with retinoic acid and HIF Inhibition by EZN-2208 (PEG-SN38) in preclinical models of PML-RAR\u03b1 and PLZF-RAR\u03b1-driven leukemia. Clin Cancer Res 2015,21(16),3685-3694","journal-title":"Clin Cancer Res"},{"key":"ref=88","doi-asserted-by":"publisher","first-page":"4432","DOI":"10.1182\/blood.V114.22.4432.4432","volume":"114","author":"Chen B-A.","year":"2009","unstructured":"Chen B-A.; Wang F.; Cheng J.; Ding J-H.; Xu W-L.; Wang X-M.; Gao C.; Wang J.; Zhao G.; Bao W.; Song H-H.; Gao F.; Zhang W.; Xia G-H.; Pei X-P.; Wu W-W.; Chen N-N.; Effect of YC-1, a HIF inhibitor, on apoptosis of leukemia cell. Blood 2009,114(22),4432","journal-title":"Blood"},{"key":"ref=89","doi-asserted-by":"publisher","first-page":"3305","DOI":"10.1002\/pmic.200700200","volume":"7","author":"Chung J.G.","year":"2007","unstructured":"Chung J.G.; Yang J.S.; Huang L.J.; Lee F.Y.; Teng C.M.; Tsai S.C.; Lin K.L.; Wang S.F.; Kuo S.C.; Proteomic approach to studying the cytotoxicity of YC-1 on U937 leukemia cells and antileukemia activity in orthotopic model of leukemia mice. Proteomics 2007,7(18),3305-3317","journal-title":"Proteomics"},{"key":"ref=90","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1515\/jbcpp-2017-0167P","volume":"30","author":"Ajith T.A.","year":"2019","unstructured":"Ajith T.A.; Current insights and future perspectives of hypoxia-inducible factor-targeted therapy in cancer. J Basic Clin Physiol Pharmacol 2019,30(1),11-18MID: 30260792","journal-title":"J Basic Clin Physiol Pharmacol"},{"key":"ref=91","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017008","volume":"6","author":"Tanturli M.","year":"2011","unstructured":"Tanturli M.; Giuntoli S.; Barbetti V.; Rovida E.; Dello Sbarba P.; Hypoxia selects bortezomib-resistant stem cells of chronic myeloid leukemia. PLoS One 2011,6(2)","journal-title":"PLoS One"},{"key":"ref=92","doi-asserted-by":"publisher","first-page":"1961","DOI":"10.1158\/1535-7163.MCT-08-0198","volume":"7","author":"Sullivan R.","year":"2008","unstructured":"Sullivan R.; Par\u00e9 G.C.; Frederiksen L.J.; Semenza G.L.; Graham C.H.; Hypoxia-induced resistance to anticancer drugs is associated with decreased senescence and requires hypoxia-inducible factor-1 activity. Mol Cancer Ther 2008,7(7),1961-1973","journal-title":"Mol Cancer Ther"},{"key":"ref=93","first-page":"247","volume":"13","author":"Shuai K.","year":"1996","unstructured":"Shuai K.; Halpern J.; ten Hoeve J.; Rao X.; Sawyers C.L.; Constitutive activation of STAT5 by the BCR-ABL oncogene in chronic myelogenous leukemia. Oncogene 1996,13(2),247-254","journal-title":"Oncogene"},{"key":"ref=94","doi-asserted-by":"publisher","first-page":"3409","DOI":"10.1182\/blood-2009-10-248211","volume":"117","author":"Warsch W.","year":"2011","unstructured":"Warsch W.; Kollmann K.; Eckelhart E.; Fajmann S.; Cerny-Reiterer S.; HAlbl, A.; Gleixner, K.V.; Dworzak, M.; Mayerhofer, M.; Hoermann, G.; Herrmann, H.; Sillaber, C.; Egger, G.; Valent, P.; Moriggl, R.; Sexl, V. High STAT5 levels mediate imatinib resistance and indicate disease progression in chronic myeloid leukemia. Blood 2011,117(12),3409-3420","journal-title":"Blood"},{"key":"ref=95","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1038\/s41375-019-0490-0","volume":"33","author":"Houshmand M.","year":"2019","unstructured":"Houshmand M.; Simonetti G.; Circosta P.; Gaidano V.; Cignetti A.; Martinelli G.; Saglio G.; Gale R.P.; Chronic myeloid leukemia stem cells. Leukemia 2019,33(7),1543-1556","journal-title":"Leukemia"},{"key":"ref=96","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3390\/cancers12010240","volume":"2","author":"Brachet-Botineau M.","year":"2020","unstructured":"Brachet-Botineau M.; Polomski M.; Neubauer H.A.; Juen L.; HA(c)dou, D.; Viaud-Massuard, M. C.; PriA(c), G.; Gouilleux, F. Pharmacological inhibition of oncogenic STAT3 and STAT5 signaling in hematopoietic cancers. Cancers 2020,2(1),240","journal-title":"Cancers"},{"key":"ref=97","year":"(Accessed\tdate: Jun 24, 2020.).","unstructured":"Pimozide Oral: Uses, Side Effects, Interactions, Pictures, Warnings"},{"key":"ref=98","doi-asserted-by":"publisher","first-page":"3421","DOI":"10.1182\/blood-2009-11-255232","volume":"117","author":"Nelson E.A.","year":"2011","unstructured":"Nelson E.A.; Walker S.R.; Weisberg E.; Bar-Natan M.; Barrett R.; Gashin L.B.; Terrell S.; Klitgaard J.L.; Santo L.; Addorio M.R.; Ebert B.L.; Griffin J.D.; Frank D.A.; The STAT5 inhibitor pimozide decreases survival of chronic myelogenous leukemia cells resistant to kinase inhibitors. Blood 2011,117(12),3421-3429","journal-title":"Blood"},{"key":"ref=99","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1038\/leu.2011.338","volume":"26","author":"Bar-Natan M.","year":"2012","unstructured":"Bar-Natan M.; Nelson E.A.; Walker S.R.; Kuang Y.; Distel R.J.; Frank D.A.; Dual inhibition of Jak2 and STAT5 enhances killing of myeloproliferative neoplasia cells.  Leukemia 2012,26(6),1407-1410","journal-title":"Leukemia"},{"key":"ref=100","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.canlet.2012.04.003","volume":"323","author":"Yun U.J.","year":"2012","unstructured":"Yun U.J.; Park S.E.; Jo Y.S.; Kim J.; Shin D.Y.; DNA damage induces the IL-6\/STAT3 signaling pathway, which has anti-senescence and growth-promoting functions in human tumors. Cancer Lett 2012,323(2),155-160","journal-title":"Cancer Lett"},{"key":"ref=101","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201800819","volume":"7","author":"Wang L.","year":"2018","unstructured":"Wang L.; Niu M.; Zheng C.; Zhao H.; Niu X.; Li L.; Hu Y.; Zhang Y.; Shi J.; Zhang Z.; A Core-shell nanoplatform for synergistic enhanced sonodynamic therapy of hypoxic tumor via cascaded strategy. Adv Healthc Mater 2018,7(22)","journal-title":"Adv Healthc Mater"},{"key":"ref=102","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/s00109-016-1498-9","volume":"95","author":"Zeng M.","year":"2017","unstructured":"Zeng M.; Shen J.; Liu Y.; Lu L.Y.; Ding K.; Fortmann S.D.; Khan M.; Wang J.; Hackett S.F.; Semenza G.L.; Campochiaro P.A.; The HIF-1 antagonist acriflavine: visualization in retina and suppression of ocular neovascularization. J Mol Med (Berl) 2017,95(4),417-429","journal-title":"J Mol Med (Berl)"}],"container-title":["Current Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200908114411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/185708\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0929867327666200908114411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,9]],"date-time":"2022-08-09T18:31:29Z","timestamp":1660069889000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/185708\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":102,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0929867327666200908114411","relation":{},"ISSN":["0929-8673"],"issn-type":[{"value":"0929-8673","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-05-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-10","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-06-25","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-04-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}